A clinical trial to study the effects of two drugs, prasugrel and clopidogrel in patients with acute coronary syndrome who are to undergo percutaneous intervention

INTERVENTION: Intervention1: Prasugrel: Loading Dose: 60mg, Maintenance dose: 10mg Control Intervention1: Clopidogrel: Loading dose:300mg, Maintenance Dose: 75mg CONDITION: Acute coronary syndrome patients PRIMARY OUTCOME: ? Inhibition of platelet aggregation (IPA) ; ? Nonfatal MI, or nonfatal stroke or rehospitalization due to a cardiac ischemic event.; ‐‐‐‐‐‐Timepoint: SECONDARY OUTCOME: ? Death from cardiovascular causes, ; ? Urgent target‐vessel revascularization; ‐‐‐‐‐‐Timepoint: INCLUSION CRITERIA: Inclusion Criteria  Patients with Acute coronary syndrome (UA/ NSTEMI or STEMI) who are to undergo PCI  Males and Females ≥18 to ≤75 years  Patients with body weight ≥ 60 kg  Patients willing to adhere to the protocol requirements  Patients able to provide free, willing and written informed consent.  For women of childbearing potential only, test negative for pregnancy between ACS presentation and enrolment (based on a urine pregnancy test) and agree to use a reliable method of birth control during the study